Abstract 1845P
Background
ICIs are used in many solid tumors and is better tolerated than chemotherapy. However, irAEs are a concerning toxicity. Studies suggest that BMI may influence irAEs rates. We conducted a population-level study to evaluate BMI on irAEs and acute care use in patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of solid tumors patients initiating ICI therapy in Ontario, Canada from June 2012-October 2018. We collected information on socio-demographics including BMI at start of ICI, clinical covariates and outcomes including acute care use and irAEs within 120 days of the last ICI dose. Multivariable Fine Gray competing risk analyses evaluated the impact of BMI on irAEs and acute care use, treating death as a competing event.
Results
Among 4683 patients, median age was 67, 57% were male; 46% had lung cancer, 35% melanoma, 9% renal; Median BMI was 26.1 (3% low, 29% normal, 27% overweight, 19% obese). Overall, 57% had an acute care episode while 7% of patients had an irAE requiring hospitalization. Increased BMI was associated with increased rate of irAEs (aHR=1.03 per 1 unit increase, 95% CI [1.01-1.04] p<0.001). Compared to patients with normal BMI, obese (aHR=1.60 [1.21-2.11] p<0.001) patients had a higher rate of irAEs. Subgroup analysis by gender found that females with increasing BMI (aHR=1.03 per unit increase [1.00-1.06] p=0.02) and obesity (aHR=2.01 [1.30-3.09] p=0.002) had higher rates of irAEs. Disease site analyses found that in patients with melanoma, obesity when compared to normal BMI (aHR=1.67 [1.10-2.53] p=0.02) was associated with increase in irAEs. In particular, in females with melanoma, obesity compared to normal BMI was strongly associated with increased irAEs (aHR=2.60 [1.36-4.96] p<0.004). BMI was not associated with overall general acute care use as a continuous or categorical variable (p>0.05).
Conclusions
Increasing BMI and obesity is associated with increasing risk for irAEs but not acute care use. The association was strongest for female patients and those with melanoma. Further research is needed to understand the mechanism of action behind this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Eng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1842P - The experience of women with breast or gynecological cancer after participation in the online mindfulness-based cancer recovery program (eMBCR)
Presenter: Marie-Estelle Gaignard
Session: Poster session 12
1843P - Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial
Presenter: Davide Smussi
Session: Poster session 12
1844P - 3-year experience of the Belgian multidisciplinary immunotoxicity board (BITOX): A nationwide initiative of the Belgian Society of Medical Oncology (BSMO)
Presenter: Marthe Verhaert
Session: Poster session 12
1846P - Social determinants of health in studies assessing toxicities associated with immune checkpoint inhibitor treatment: A systematic review
Presenter: Sofia Georgopoulou
Session: Poster session 12
1847P - Safety and efficacy of immune checkpoint inhibitors in patients over 85 years: ICIPO85 study
Presenter: MYRTILLE THOMAS
Session: Poster session 12
1848P - Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience
Presenter: Onur Bas
Session: Poster session 12
1849P - Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 12
1850P - Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
Presenter: Jesús Peña-Lopez
Session: Poster session 12
1851P - Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis
Presenter: Taha Koray Sahin
Session: Poster session 12
1852P - The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review
Presenter: Poorni Jaganathan
Session: Poster session 12